

METHODS FOR DETERMINING STEROID RESPONSIVENESS

Field of the Invention

The invention relates to a diagnostic assay for steroid responsiveness.

Background of the Invention

Many diseases (e.g., rheumatoid arthritis, inflammatory bowel diseases, systemic lupus erythematosus, asthma) that are primarily inflammatory, or that have a major inflammatory component, are treated with steroids such as prednisone. In addition, some cancers are treated with steroids, as are transplant recipients, to avoid transplant rejection. However, the effectiveness of steroids varies from patient to patient and is usually impossible to predict. Some patients may be constitutively non-responsive to a particular medication, and others may become refractory to treatment over time. In some cases, patients may experience symptomatic relief, but attempts to withdraw therapy lead to disease flare. As a consequence, the inclination for doctors to continue steroid therapy and even to increase the dosage of a steroid is associated with serious, cumulatively debilitating, side effects. The clinical screening of patients who are candidates for steroid therapy for their ability to respond to steroids and the monitoring of patients who are undergoing steroid therapy but who may be transitioning from steroid responder to non-responder (i.e., refractory) status is therefore of significant clinical importance.

A need therefore exists for a diagnostic assay or test for steroid responsiveness.

Summary of the Invention

The invention provides diagnostic assays for measuring the response to a drug by comparing mRNA levels expressed by a gene that is expected to respond to the drug to mRNA levels expressed by a gene that is not expected to respond to the drug. The invention is based on observations that expression in drug-sensitive genes is useful as a marker for the cellular response to the drug. Methods according to the invention are

useful for predicting the ability of a patient (or a tissue, body fluid or cell sample *in vitro*) to respond to a treatment before treatment begins and to monitor treatment over time to assess continued responsiveness to therapeutic intervention.

In one aspect, the invention provides methods for determining steroid responsiveness in a subject, by determining the level of expression of RNA from a first gene known or suspected to be steroid responsive, determining the level of expression of RNA from a second gene known or suspected to be non-responsive to steroids, and comparing them pre- and post-treatment to determine whether the subject is likely to respond to steroid treatment. The subject is determined to be steroid responsive if the level of expression from the first gene is higher than that from the second gene and the subject is non-responsive to steroids if the level of expression from the second gene is higher than that from the first gene. Alternatively, the ratio of the expression from the first gene to the expression from the second gene is compared to predetermined control ratios from untreated subjects or to predetermined control ratios from subjects undergoing successful treatment. For example, a subject may be steroid responsive if the ratio of the expression from the steroid responsive gene to the expression of the steroid non-responsive gene is similar to prior ratios for the subject when previously responsive or higher than the predetermined control ratio for untreated subjects or similar to predetermined control ratios from subjects undergoing successful treatment. Conversely, the subject may be steroid non-responsive if the ratio of the expression from the steroid responsive gene to the expression of the steroid non-responsive gene is lower than prior ratios for the subject when previously responsive or similar to the predetermined control ratio for untreated subjects or lower than predetermined control ratios from subjects undergoing successful treatment.

In another embodiment, the invention provides methods for determining steroid responsiveness in a tissue, body fluid or cell after exposure *in vitro* to a steroid.

In another embodiment, the invention provides methods for determining or predicting steroid responsiveness in a subject before and after (i.e., following or during administration of) steroid treatment. Samples are taken before and after steroid

treatment, and the RNA levels for the steroid non-responsive gene are used as a normalizing control for the RNA levels of the steroid responsive gene. The invention provides for obtaining a pre-treatment tissue, body fluid or cell from a subject, determining the level of RNA expression from steroid responsive and steroid non-responsive genes, administering a steroid to the subject, obtaining a post-treatment tissue, body fluid or cell from the subject and determining a post-treatment RNA level expressed from the same genes identified in the pre-treatment samples, comparing the pre-treatment level of RNA expressed from the first gene to the pre-treatment level of RNA expressed from the second gene to create a first normalized value, comparing the post-treatment level of RNA expressed from the first gene to the post-treatment level of RNA expressed from the second gene to create a second normalized value, and comparing the first normalized value to the second normalized value. If the first normalized value is less than the second normalized value, the tissue, body fluid or cell sample is determined to be steroid responsive and if the first normalized value is greater than or the same as the second normalized value the tissue, body fluid or cell sample is determined to be steroid non-responsive. The difference between the first normalized value and the second normalized value correlates to the ability of the subject to respond to steroid treatment.

In another embodiment, the invention provides methods for determining an effective dose of a steroid in a subject by administering to a subject a dose of a steroid, obtaining a tissue, body fluid or cell sample from the subject, determining the level of expression of RNA from a first gene known or suspected to be steroid responsive, determining the level of expression of RNA from a second gene known or suspected to be non-responsive to steroids, and comparing them pre- and post-treatment to determine whether the dose of steroid is appropriate. Alternatively, the ratio of the expression from the first gene to the expression from the second gene is compared to predetermined control ratios from untreated subjects. This alternative allows for the continued assessment of effective dosage during a course of treatment if no pre-treatment sample is available, e.g., in the case of a chronic condition. For example, a subject may be receiving an adequate dosage of steroid if the ratio of the expression from the first gene to the expression from the second gene is higher than the predetermined control ratio for untreated subjects. The dosage may be titrated or lowered until just before the ratio of

RNA levels from the steroid responsive to steroid non-responsive gene begins to decrease, in order to determine the minimum dosage that can be given to achieve optimal results. Alternatively, a subject may be given an initial low dose of steroid, the ratio of RNA levels from the steroid responsive to steroid non-responsive gene measured, and the
5 dosage increased until the ratio reaches a plateau, or until the ratio reaches a desired target level.

In some cases a patient may be obtaining clinical benefit (e.g., symptomatic relief) from steroid therapy to later become refractory (i.e., non-responsive to the therapy). The instant invention provides methods for ensuring the long-term
10 appropriateness and efficacy of a steroid treatment by monitoring a subject's ability to respond to the steroid. The invention provides methods for monitoring a subject's ability to respond to a steroid by administering to a subject a dose of steroid, obtaining a tissue, body fluid or cell sample from the subject, determining the level of expression of RNA from a first gene known or suspected to be steroid responsive, determining the level of
15 expression of RNA from a second gene known or suspected to be non-responsive to steroids, and comparing them pre- and post-treatment to determine whether the subject is still responsive to steroid treatment. The subject is still steroid responsive if the level of expression from the steroid responsive gene is higher than that of the steroid non-responsive gene and the subject has become non-responsive to steroids if the level of
20 expression from the steroid non-responsive gene is higher than that of the steroid responsive gene. Alternatively, the ratio of the expression from the steroid responsive gene to the expression from the steroid non-responsive gene is compared to predetermined control ratios from untreated subjects or to predetermined control ratios from subjects undergoing successful treatment or to a preexisting ratio from the subject
25 obtained at a time when the subject was classified as steroid responsive. For example, a subject may be steroid responsive if the ratio of the expression from the steroid responsive gene to the expression of the steroid non-responsive gene is similar to prior ratios for the subject when previously responsive or higher than the predetermined control ratio for untreated subjects or similar to predetermined control ratios from
30 subjects undergoing successful treatment. Conversely, the subject may be steroid non-responsive if the ratio of the expression from the steroid responsive gene to the

expression of the steroid non-responsive gene is lower than prior ratios for the subject when previously responsive or similar to the predetermined control ratio for untreated subjects or lower than predetermined control ratios from subjects undergoing successful treatment.

5 More generally, the invention also provides a general approach to determining drug responsiveness generally in a subject undergoing drug treatment. In this method a first gene must be identified which responds to the drug by causing a change in RNA production (e.g., change in transcription, RNA stability, or RNA accumulation). A second gene must also be identified which does not respond to the drug by causing a
10 change in RNA production. In another aspect, the invention provides methods for determining drug responsiveness in a subject undergoing drug treatment by determining the level of expression of RNA from a first gene known or suspected to be drug-responsive, determining the level of expression of RNA from a second gene known or suspected to be non-responsive to the drug, and comparing them pre- and post-treatment
15 to determine whether the subject is likely to respond to drug treatment. The subject is determined to be drug-responsive if the level of expression from the drug-responsive gene is higher than that of the drug non-responsive gene and the subject is non-responsive to the drug if the level of expression from the drug non-responsive gene is higher than that of the drug-responsive gene. Alternatively, the ratio of the expression from the drug-
20 responsive gene to the expression from the drug non-responsive gene is compared to predetermined control ratios from untreated subjects or to predetermined control ratios from subjects undergoing successful treatment. For example, a subject may be drug-responsive if the ratio of the expression from the drug-responsive gene to the expression of the drug non-responsive gene is similar to prior ratios for the subject when previously
25 responsive or higher than the predetermined control ratio for untreated subjects or similar to predetermined control ratios from subjects undergoing successful treatment. Conversely, the subject may be drug non-responsive if the ratio of the expression from the drug-responsive gene to the expression of the drug non-responsive gene is lower than prior ratios for the subject when previously responsive or similar to the predetermined
30 control ratio for untreated subjects or lower than predetermined control ratios from subjects undergoing successful treatment.

In another embodiment, the invention provides methods for determining drug responsiveness in a tissue, body fluid or cell after exposure *in vitro* to a drug.

In another embodiment, the invention provides methods for determining responsiveness in a tissue, body fluid or cell sample to a drug or drug candidate for
5 determining alterations in the cellular response to pro-inflammatory, anti-inflammatory or immune response-modifying stimuli (e.g., cytokines, chemokines, steroids, etc.). In other words, the methods according to the invention may detect side effects of drugs on immune responses in cells. The cellular response may be assessed by comparing the relative levels of endogenous steroid responsive gene and steroid nonresponsive gene
10 mRNA, as described herein. Alternatively, cells may be transfected with a vector or vectors having the steroid responsive gene and steroid nonresponsive gene promoters, each in operative linkage with a different detectable reporter gene (e.g., green fluorescence protein or yellow fluorescence protein). The method includes exposing the cell, transfected with the vector(s) having the steroid responsive gene and steroid
15 nonresponsive gene promoter-driven reporter genes, to a drug of interest and comparing the level of expression from the first reporter gene to the level of expression from the second reporter gene. In this way, a drug that may or may not have pro- or anti-inflammatory or immune response-modifying activity can be assayed for its effect on gene expression from the steroid responsive gene and steroid nonresponsive gene
20 promoters.

In a preferred embodiment, RNA levels are quantified by amplification of the RNA by, for example, reverse transcription polymerase chain reaction (RT-PCR) of the RNAs. The reaction products may be quantified, e.g., by gel electrophoresis (e.g., slab or capillary) or the unamplified RNA may be quantified, e.g., by Northern blot analysis, or
25 by direct hybridization with a probe. Alternatively, RNA levels are quantified by *in situ* detection. Diagnostic procedures may also be performed *in situ* directly upon sections (fixed or frozen) of tissue obtained from biopsies or resections by looking at relative intensities of drug or steroid responsive and drug or steroid nonresponsive RNAs in a portion of the biopsy sample, such that no nucleic acid purification is necessary. Nucleic
30 acid reagents may be used as probes and/or primers for such *in situ* procedures.

RNA may be quantified from any tissue, body fluid or nucleated cell sample. For example, the tissue or body fluid sample is preferably blood. The tissue sample may be derived from a biopsy of any tissue in which the genes of interest (i.e., the drug or steroid responsive gene and the drug or steroid non-responsive gene) are expressed. The tissue, body fluid or cell sample may contain one or more of monocytes, macrophages, neutrophils, T-cells, B-cells, basophils, fibroblasts, smooth muscle cells, endothelial cells and epithelial cells, for example. In addition, the tissue or cell sample may be a benign tumor, malignant tumor, a tissue that is normally responsive to steroids (such as a breast cancer biopsy sample, e.g., to determine whether it has lost the ability to respond to steroids, has become less responsive to steroids, or has become more responsive to steroids) or a tissue that is non-responsive to steroids (e.g., to determine if it has gained responsiveness to steroids). In a preferred embodiment, the tissue used to measure RNA levels of the genes of interest contains buccal cells. The tissue, body fluid or cell sample is obtained and is preferably stored in a stabilization solution or is stored frozen prior to analysis to minimize RNA degradation.

In another embodiment of the invention, the methods involve the step of administering one or more pro-inflammatory or anti-inflammatory mediators to the tissue, body fluid or cell, such as interleukin 1α (IL- 1α), interleukin- 1β (IL- 1β), interleukin 6 (IL-6), and tumor necrosis factor (TNF- α). In addition, the anti-inflammatory mediator may be interleukin 1 receptor antagonist (IL-1RA), tumor necrosis factor receptor antagonist (TNF-RA) or derivatives thereof, soluble TNF receptors, or anti-TNF antibodies, for example. Methods according to the invention may involve the step of administering one or more cytokines, chemokines (e.g., interleukin-8 (IL-8)), interferons, or other hormones (e.g., vasoactive intestinal peptide (VIP)).

Although the methods according to the invention may be used to predict, determine, measure or monitor the responsiveness of a subject to any drug that may cause an increase in RNA levels of at least one gene but that does not cause an increase in RNA levels of at least one other gene, the assay is ideally suited for predicting, determining, measuring or monitoring the responsiveness of a subject to steroids.

In a preferred embodiment, differential cytokine-dependent or cytokine-independent transcriptional activities of the steroid responsive and steroid nonresponsive genes in the presence or absence of glucocorticoids is used to measure steroid responsiveness. The preferred genes of interest for measuring steroid responsiveness are derived from the serum amyloid A (SAA) gene superfamily. One SAA gene, serum amyloid A1 (*SAA1*), is responsive to glucocorticoids both *in vivo* and *in vitro*, causing an increase in transcription of *SAA1* RNA and a concomitant increase in *SAA1* RNA levels. Another SAA gene, serum amyloid A2 (*SAA2*) is not responsive to glucocorticoids. Thus, a preferred steroid responsive gene according to the invention is *SAA1* and a preferred steroid non-responsive gene is *SAA2*. Alternatively, the steroid responsive gene may encode another acute phase reactant, chemokine, cytokine agonist, cytokine antagonist, complement component, or other gene that is responsive to steroids (i.e., steroid treatment causes an increase in RNA levels). Accordingly, the steroid-non-responsive gene may encode an acute phase reactant, chemokine, cytokine agonist, cytokine antagonist, complement component, or other gene which is not responsive to steroids (i.e., steroid treatment does not cause an increase in RNA levels).

SAA1 transcription, but not *SAA2* transcription, is induced in response to steroids in the absence of cytokines in some cell types (e.g., oral epithelial). Other cell types (e.g., HEPG2 hepatoma) require the presence of endogenous (e.g., due to ongoing inflammation), or exogenously administered cytokines, to achieve induction of *SAA1* and *SAA2* transcription which permits a subsequent or coincident steroid-dependent transcriptional enhancement of the *SAA1* but not the *SAA2* gene. Cell types which do not require such exposure to endogenous or exogenous cytokines are particularly useful for determining steroid responsiveness in a non-inflamed individual (e.g., a pre-surgery, pre-transplantation, or pretreatment patient).

In another preferred embodiment, the methods according to the invention may be used to evaluate steroid responsiveness in response to the administration of a combination of stimuli or drugs, such as one or more of IL-1, IL-6 and TNF- α , and may thereby be useful in evaluating therapies under a range of inflammation conditions and/or treatment modalities. For example, the steroid responsive and non-responsive genes according to

the methods of the invention may be chosen depending upon their ability to respond to IL-1 and IL-6, administered separately or in combination, with or without steroids. For example, both the *SAA1* gene and *SAA2* genes respond to IL-1 strongly and IL-6 weakly, but only the responses of the *SAA1* gene are augmented by glucocorticoid administration.

5 By comparison, the C reactive protein gene (*CRP*) responds weakly to IL-1 and strongly to IL-6, and both responses are augmented by glucocorticoid administration. The SAA genes and the CRP gene are therefore markers for subsets of genes that respond differentially to certain cytokines alone or in combination with steroids and/or other drugs. Thus, a comparison of the RNA levels of the SAA genes and the CRP genes,
10 and/or other genes, may provide useful RNA profiles which predict, determine, measure or monitor a subject's ability to respond to steroids at certain points during an acute phase response (i.e., depending upon the "mix" of cytokines present at that point in time) or to certain cytokines, cytokine antagonists, anti-inflammatory or other drug treatments in the absence of, or in combination with, endogenous or exogenous (i.e., therapeutically
15 administered) steroids.

Methods according to the invention may therefore further include the step of quantifying the RNA level of a third gene, or additional genes, and comparing the RNA level from the third or additional genes to the RNA levels of the steroid responsive gene and the RNA level of the steroid non-responsive gene. In a preferred embodiment, the
20 third gene may encode an acute phase reactant, chemokine, cytokine agonist, cytokine antagonist, or complement component. Exemplary third genes are *CRP*, complement component 3 (*C3*), Factor B, or albumin.

Methods according to the invention are preferably used to predict, determine, measure or monitor the steroid responsiveness of a subject who suffers from an
25 inflammatory condition, a disease with an inflammatory component, a disease with an inflammatory consequence, and/or a disease with inflammatory symptoms. The subject may be assayed to determine if he or she will respond to, will not respond to, is refractory to, is less responsive to, or is more responsive to steroid treatment, or is steroid dependent. Methods according to the invention are particularly useful for predicting,
30 determining, measuring or monitoring the steroid responsiveness of a subject who suffers

from an arthritic disease such as, for example, osteoarthritis, rheumatoid arthritis, psoriatic arthritis or idiopathic arthritis. Methods according to the invention are also useful for predicting, determining, measuring or monitoring the steroid responsiveness of a subject who suffers from an autoimmune disease, such as an inflammatory bowel

5 disease (e.g., Crohn's disease or ulcerative colitis). Other diseases and conditions that have an inflammatory component or consequence include, but are not limited to, asthma, adult respiratory distress syndrome, systemic lupus erythematosus, multiple sclerosis, insulin-dependent diabetes mellitus, autoimmune arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, inflammatory pulmonary syndrome, pemphigus vulgaris, idiopathic

10 thrombocytopenic purpura, cerebral edema, autoimmune meningitis, myasthenia gravis, autoimmune thyroiditis, sarcoidosis, dermatitis, atopic dermatitis, eczematous dermatitis, psoriasis, Sjogren's Syndrome, sarcoidosis, keratoconjunctivitis sicca secondary to Sjogren's Syndrome, alopecia areata, allergic responses due to arthropod bite reactions, aphthous ulcer, iritis, conjunctivitis, keratoconjunctivitis, cutaneous lupus erythematosus,

15 scleroderma, vaginitis, proctitis, drug eruptions, Stevens-Johnson syndrome, leprosy reversal reactions, erythema nodosum leprosum, autoimmune uveitis, allergic encephalomyelitis, aplastic anemia, pure red cell anemia, autoimmune destruction of erythrocytes, idiopathic thrombocytopenia, polychondritis, Wegener's granulomatosis, chronic active hepatitis, alcohol liver disease, Graves ophthalmopathy, primary biliary

20 cirrhosis, uveitis posterior and interstitial lung fibrosis.

Alternatively, methods according to the invention are used to determine steroid responsiveness in a subject who is being evaluated as a candidate for, is about to undergo, or has undergone a tissue or organ transplant. Alternatively, the subject has cancer, is being treated for cancer, or is in remission for cancer (e.g., solid tumors, acute

25 lymphocytic leukemia and lymphoma). Alternatively, the subject suffers from or the assay is used to diagnose or monitor, a renal disease, allergy, infectious disease, ocular disease, skin disease, gastrointestinal disease, endocrine disease, stroke, coronary artery disease, vascular disease, atherothrombotic disease, spinal cord injury, acute adrenal insufficiency, chronic primary adrenal insufficiency, secondary adrenal insufficiency,

30 and/or congenital adrenal hyperplasia. Alternatively, the subject is being evaluated as a

candidate for, is about to undergo, or has undergone steroid replacement or substitution therapy.

In a preferred embodiment of the invention, the steroid responsive gene is controlled by a steroid responsive element, such as a glucocorticoid responsive element (GRE). The GRE may be a consensus GRE or a non-consensus GRE. The consensus GRE is preferably GGTACAnnnTGGTCT (SEQ ID NO:1), where n is any nucleotide (A, G, C or T), or a variation thereof. Alternatively, the first gene is controlled either in *cis* or in *trans* (e.g., in each case either proximally or distally) by a non-consensus element that permits the gene to respond to steroids. The steroid may provide a signal via the glucocorticoid receptor (GR) or via another steroid (e.g., estrogen, progesterone, etc.) receptor that may engage the GRE and/or another steroid response element in the steroid responsive gene, or at another genomic location. In a preferred embodiment, the steroid non-responsive gene is encoded by a gene which is not controlled by a steroid response element.

The steroid used in the methods according to the invention may be, for example, a glucocorticoid, an estrogen, or an androgen. Exemplary steroids include, but are by no means limited to, alclometasone dipropionate, amcinonide, beclomethasone dipropionate, betamethasone, betamethasone benzoate, betamethasone dipropionate, betamethasone sodium phosphate, betamethasone sodium phosphate and acetate, betamethasone valerate, clobetasol propionate, clocortolone pivalate, cortisol (hydrocortisone), cortisol (hydrocortisone) acetate, cortisol (hydrocortisone) butyrate, cortisol (hydrocortisone) cypionate, cortisol (hydrocortisone) sodium phosphate, cortisol (hydrocortisone) sodium succinate, cortisol (hydrocortisone) valerate, cortisone acetate, desonide, desoximetasone, dexamethasone, dexamethasone acetate, dexamethasone sodium phosphate, diflorasone diacetate, fludrocortisone acetate, flunisolide, fluocinolone acetonide, fluocinonide, fluorometholone, flurandrenolide, halcinonide, medrysone, methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate, mometasone furoate, paramethasone acetate, prednisolone, prednisolone acetate, prednisolone sodium phosphate, prednisolone tebutate, prednisone,

triamcinolone, triamcinolone acetonide, triamcinolone diacetate, and triamcinolone hexacetonide or a synthetic analog thereof, or a combination thereof.

The invention further contemplates the administration of one or more steroid inhibitors or steroid antagonists. Exemplary steroid inhibitors include, but are not limited to, mitotane, metyrapone, aminoglutethimide, ketoconazole, and trilostane.

The steroid may be administered any number of ways, including, for example, parenterally, orally, locally, rectally, intravenously, topically, intramuscularly, enterally, transdermally, nasally, ocularly, transmucosally, via inhalation, and/or subcutaneously.

In another aspect, the invention provides a kit for determining drug (e.g., steroid) responsiveness in a subject which has a probe specific for, or primers specific for amplifying, RNA encoded by a drug-responsive gene and probes specific for, or primers specific for amplifying, RNA encoded by a drug non-responsive gene. Preferably, the kit also has a tissue, body fluid or cell collector. In a preferred embodiment, the collector contains RNase inhibitors and other inhibitors and preservatives for minimizing degradation of RNA and DNA. For example, a PAXgeneTM Blood RNA tube (Qiagen, Hilden, Germany) may be used.

Brief Description of the Drawings

The foregoing and other objects, features and advantages of the present invention, as well as the invention itself, will be more fully understood from the following description of preferred embodiments when read together with the accompanying drawings, in which:

Figure 1 is an alignment of *SAA1* and *SAA2* promoters. The proximal 450 bases of the human *SAA1* and *SAA2* promoters (SEQ ID Nos: 2 and 3) were aligned using the ClustalW program. Putative transcription factor binding sites are underlined once (predicted by TESS program), with dots (predicted by Signalscan program) or twice (predicted by visual inspection). Dashes represent gaps in one sequence relative to the other. The Xma1 site is boxed.

Figure 2 is a timecourse of the induction of *SAA1* and *SAA2* promoter luciferase reporter constructs in the presence or absence of cytokine and/or dexamethasone treatment. HepG2 cells transfected with pGL2-SAA2pt (A) or pGL2-SAA1pt (B) luciferase reporter constructs were treated with medium only, dexamethasone (50nM), IL-1 (10ng/ml), IL-1 plus dexamethasone,

IL-6 (10ng/ml), IL-6 plus dexamethasone, IL-1 plus IL-6, or IL-1 plus IL-6 plus dexamethasone. Cells were harvested 3, 6, 9 and 24 hours after treatment and relative luciferase values were calculated and compared to untreated controls.

Figure 3 shows that *SAA1* glucocorticoid responsiveness is dose dependent. HepG2 cells transfected with pGL2-SAA1pt or pGL2-SAA2pt were treated with increasing amounts of dexamethasone (10nM, 50nM, 100nM, 500nM, 1μM) in the absence or presence of 10ng/ml IL-1 plus 10ng/ml IL-6. Cells were harvested 4 hours after treatment and relative luciferase values were calculated and compared to untreated controls.

Figure 4 shows that *SAA1* glucocorticoid responsiveness is glucocorticoid receptor (GR) dependent. HepG2 cells were transfected with pGL2-SAA1pt and treated with 10ng/ml IL-1 plus 10ng/ml IL-6, alone and in the presence of 10nM RU486 and/or 100nM dexamethasone. Cells were harvested 4 hours after treatment and relative luciferase values were calculated and compared to untreated controls.

Figure 5 shows that *SAA1* glucocorticoid responsiveness is dependent on cytokine driven transcriptional activation. HepG2 cells co-transfected with the pGL2-SAA1[0.25] (A) or pGL2-SAA2[0.25] (B) and 0, 5, 25 or 50ng/well CMX-GR expression construct were treated with increasing amounts of dexamethasone (0, 50nM, 500nM, 5μM) in the absence or presence of 10ng/ml IL-1 plus 10ng/ml IL-6. Cells were harvested 4 hours after treatment and relative luciferase values were calculated and compared to untreated controls.

Figure 6 shows cytokine and dexamethasone induction of chimeric *SAA* promoters. (A) Schematic diagram of the chimeric *SAA* promoter constructs. Sequence derived from *SAA1* is represented by pale gray shading; sequence derived from *SAA2* is represented by dark gray shading; the luciferase coding sequence is represented by "Luc"; the transcription start site is indicated with an arrow. The positions of the Xma 1 restriction enzyme sites used for generating the chimeras are indicated. The putative GRE is represented by a black box. (B) Chimeric constructs were transfected into HepG2 cells and treated with medium only, 50nM dexamethasone, 10ng/ml IL-1 plus 10ng/ml IL-6, or IL-1 plus IL-6 plus dexamethasone. Cells were harvested 4 hours after treatment and relative luciferase values were calculated and compared to untreated controls.

Figure 7 shows GRE mutant *SAA* promoters. (A) Alignment of the region of *SAA1* encompassing the GRE, the corresponding regions of *SAA2*, the mutants GRE1 and GRE2 and

the consensus GRE sequence. (B) HepG2 cells were transfected with pGL2-SAA1[0.7], GREI, GRED or pGL2-SAA2[0.7] constructs and treated with medium only, 50nM dexamethasone, 10ng/ml IL-1 plus 10ng/ml IL-6, or IL-1 plus IL-6 plus dexamethasone. Cells were harvested 4 hours after treatment and relative luciferase values were calculated and compared to untreated controls.

Figure 8 shows the response of the endogenous human *SAA1* and *SAA2* genes to cytokines and dexamethasone. (A) Alignment of the 335bp *SAA1* (nucleotides 187 to 273 of SEQ ID NO:4; nucleotides 404 to 520 of SEQ ID NO:5) and 361bp *SAA2* (nucleotides 187 to 273 of SEQ ID NO:6; nucleotides 404 to 546 of SEQ ID NO:6) RT-PCR product sequences. The numbering refers to the full mRNA sequences. The intron exon boundary is marked with a vertical line, amplification from genomic DNA would generate a product that incorporates sequence encompassing the 384bp (*SAA1*) or 394bp (*SAA2*) intron at this position. The 3' UTRs are underlined once and the primer sequences are underlined twice. Diagonal lines represent 121 bases of aligned sequences which contain no gaps. Dashes represent regions of the *SAA2* 3'UTR that have no counterpart in the *SAA1* 3'UTR. (B) HepG2 cells were treated with medium only, 100nM dexamethasone, 10ng/ml IL-1 plus 10ng/ml IL-6 or IL-1 plus IL-6 plus dexamethasone for 24 hours. RNA was extracted, reverse transcribed and amplified as described. PCR products were separated by 8% polyacrylamide gel electrophoresis. This image depicts the relative amounts of SAA1 and SAA2 product within each sample.

Detailed Description of the Invention

The invention provides diagnostic assays for measuring the responsiveness of a subject, tissue, body fluid, or cell sample to a drug by comparing the mRNA levels of a gene that responds to the drug, such as a steroid, to the mRNA levels of a gene that does not respond to the drug. Methods according to the invention are useful to predict the ability of a subject (or a tissue, body fluid or cell sample *in vitro*) to respond to a drug or steroid before and at any stage of treatment, and to monitor the subject over time to assess continued responsiveness to the drug or steroid.

The preferred genes for measuring steroid responsiveness, for example, are serum amyloid A1 (*SAA1*), which is responsive to glucocorticoids both *in vivo* and *in vitro*, and serum amyloid A2 (*SAA2*), which is not responsive to glucocorticoids. Luciferase

reporter constructs carrying the *SAA1* and *SAA2* promoters were used to demonstrate dose-dependent glucocorticoid enhancement of cytokine driven *SAA1* transcription. Using reporter constructs carrying chimeric and mutant *SAA* promoters, the putative GRE in the *SAA1* promoter was confirmed to be functional. *SAA1* and *SAA2* promoters exhibit qualitatively similar induction profiles in response to cytokines, but the *SAA2* promoter had a significant basal and cytokine driven transcriptional advantage (i.e., between 2 and 3 fold) over the *SAA1* promoter (see Example 1). The addition of the synthetic glucocorticoid dexamethasone to cytokine treated cells specifically enhanced readout from the *SAA1* promoter to a level that is similar to that of the *SAA2* promoter. A combination of sequence alignment and *in vitro* experiments using reporter constructs carrying *SAA1/SAA2* promoter chimeras and *SAA1* and *SAA2* promoters that had been modified by site specific mutagenesis identified a functional glucocorticoid response element (GRE) in the *SAA1* promoter only.

An RT-PCR based method was used to distinguish between the products generated by amplification from the *SAA1* and *SAA2* mRNAs (see Example 2). This method exploits differences in the 3'-untranslated regions (UTRs) of the transcripts, resulting in *SAA1* mRNA being 26 residues shorter than *SAA2* mRNA. Primers flanking the regions that contribute to this size disparity were used to amplify products of 335 and 361 base pairs (bp) from cDNA generated from the *SAA1* and *SAA2* mRNAs, respectively. The amplification products were resolved on 8% polyacrylamide gels and quantified by image analysis using NIH Image. Application of this method to total RNA extracted from HepG2 cells yielded results that parallel those obtained with the promoter reporter constructs. The ratio of *SAA1* product to *SAA2* product was 2:5 following treatment with IL-1 plus IL-6, indicating that the endogenous *SAA2* gene has a significant transcriptional advantage (i.e., about 2.5 fold) when induced by cytokines in the absence of glucocorticoids. In contrast, the ratio of *SAA1* to *SAA2* product, from cells treated with IL-1 plus IL-6 plus dexamethasone was 5:4, indicating a "switch" in transcriptional advantage from *SAA2* to *SAA1* in the presence of steroids.

In the liver, upregulation of A-SAA protein synthesis during the acute phase response (APR) appears to be a two step process involving an initial cytokine driven

phase followed by, or coincident with, a glucocorticoid enhanced cytokine dependent phase. During the first phase, in which the *SAA1* and *SAA2* promoters are engaged by the transcription factors NF-kappaB and NF-IL6, *SAA2* has a significant transcriptional advantage over *SAA1*. In the second phase only the *SAA1* promoter is additionally
5 engaged by the GR, the result of which is to enhance its transcriptional activity to a level similar to that exhibited by the *SAA2* promoter in both phases. In cells in which glucocorticoids can upregulate *SAA1* transcription, but not *SAA2* transcription, in the absence of cytokine stimulation, only the *SAA1* promoter is engaged by the GR. Thus, the ratios of SAA1 and SAA2 RNAs and proteins may change over time with a bias
10 strongly in favor of SAA2 in the early APR giving way to increasing relative amounts of SAA1 later. Furthermore, the absolute concentrations of each of the A-SAAs during chronic inflammation may depend on the nature of the underlying disease, and therefore the "mix" of pro- and anti-inflammatory mediators present. The introduction of anti-inflammatory steroid therapy may further modify the ratio of SAA1 and SAA2 mRNA
15 depending on the type and therapeutic dose of synthetic glucocorticoids used.

In a preferred embodiment, RNA levels are quantified by amplification of the RNAs by, for example, reverse transcription polymerase chain reaction (RT-PCR) and resolution/quantification of the reaction products by gel electrophoresis (e.g., slab, capillary, etc.) and product measurement (e.g., by scanning, laser, etc.) or Northern blot
20 analysis of the RNAs. Alternatively, RNA levels are quantified by *in situ* detection according to standard methods. In a preferred embodiment of the invention, probes capable of hybridizing specifically to SAA1 or SAA2 RNA, are attached to a solid phase support, e.g., a "chip" or "DNA probe array". Oligonucleotides can be bound to a solid support by a variety of processes, including lithography. For example, a chip can hold up
25 to about 250,000 oligonucleotides. The solid phase support is then contacted with a test nucleic acid and hybridization to the specific probes is detected. Accordingly, the quantification of numerous samples (e.g., different tissues from the same individual or samples from different individuals) or the profiling of the RNA levels of a number of steroid or drug responsive or non-responsive genes can be identified in a single
30 hybridization experiment.

In another embodiment, an oligonucleotide ligation assay (OLA) (U.S. Pat. No. 4,998,617) may be used. The OLA protocol uses two oligonucleotides which are designed to be capable of hybridizing to abutting sequences of a single strand of a target. One of the oligonucleotides is linked to a separation marker, e.g., biotinylated, and the other is detectably labeled. If the precise complementary sequence is found in a target molecule, the oligonucleotides hybridize such that their termini abut, and create a ligation substrate. Ligation then permits the labeled oligonucleotide to be recovered using avidin, or another biotin ligand. Nickerson, D. A. et al. ((1990) *Proc. Natl. Acad. Sci. USA* 87:8923-27) have described a nucleic acid detection assay that combines attributes of PCR and OLA. In this method, PCR is used to achieve the exponential amplification of target DNA, which is then detected using OLA.

Several techniques based on this OLA method have been developed and are useful for detecting RNA. For example, U.S. Patent No. 5,593,826 discloses an OLA using an oligonucleotide having 3'-amino group and a 5'-phosphorylated oligonucleotide to form a conjugate having a phosphoramidate linkage. In another variation of OLA described in Tobe et al. ((1996), *Nucleic Acids Res.* 24: 3728), OLA combined with PCR may permit the detection and quantification of SAA1 and SAA2 RNAs and other RNAs (e.g., CRP) in a single microtiter well. By marking each of the isoform-specific primers with a unique hapten, i.e., digoxigenin and fluorescein, each OLA reaction can be detected by using hapten specific antibodies that are labeled with different enzyme reporters, alkaline phosphatase or horseradish peroxidase. This system permits the detection of two closely related but distinct isoforms (e.g., SAA1 and SAA2 RNAs) using a high throughput format that leads to the production of two different colors. This system also permits the detection of additional RNAs, such as CRP.

RNA may be quantified from any tissue, body fluid or nucleated cell sample. In a preferred embodiment, the bodily fluid is blood that is obtained by known techniques (e.g., venipuncture). Alternatively, the methods according to the invention can be performed on dry cell samples (e.g., hair or skin) particularly when RT-PCR is used to amplify the RNA. The tissue sample may be derived from a biopsy of any tissue in which the genes of interest (i.e., the drug or steroid responsive gene and the drug or steroid non-responsive gene) are expressed.

Preparations for oral administration of a drug or steroid may be suitably formulated to give controlled release of the active compound. For buccal administration, the drug or steroids may take the form of tablets or lozenges formulated in a conventional manner. Alternatively, an area may be swabbed, sprayed or applied with a steroid or drug prior to obtaining a post-treatment sample (e.g., by scraping). For administration by inhalation, the drug or steroid for use according to the methods of the invention is conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.

In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the drug or steroid and a suitable powder base such as lactose or starch.

The drugs or steroids may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The drugs or steroids may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the drugs or steroids may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

The drugs or steroids may also be formulated in rectal drugs or steroids such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

The drugs or steroids may also be formulated as a depot preparation. For example, parenteral depot systems (PDS) are injected or implanted into the muscle or subcutaneous tissue and incorporated drug released in a controlled manner, allowing the adjustment of release rates over extended periods of time, ranging from several days up to one year. Such long acting formulations may be administered by implantation (e.g., subcutaneously or intramuscularly) or by intramuscular injection. The drugs or steroids may be formulated with suitable polymeric or hydrophobic materials (e.g., as an

emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, such as a sparingly soluble salt. Other suitable delivery systems include microspheres which offer the possibility of local noninvasive delivery of drugs over an extended period of time. This technology utilizes microspheres of precapillary size which can be injected
5 via a coronary catheter into any selected part of the body, e.g., the eye, or other organs without causing inflammation or ischemia. The administered drug or steroid is slowly released from these microspheres and taken up by surrounding tissue cells.

Systemic administration of the drug or steroid can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants
10 appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, e.g., for transmucosal administration bile salts and fusidic acid derivatives. In addition, detergents may be used to facilitate permeation. Transmucosal administration may be through nasal sprays or using suppositories. For topical administration, the oligomers of the invention are formulated
15 into ointments, salves, gels, or creams as generally known in the art. A wash solution may be used locally to treat an injury or inflammation to accelerate healing.

The invention further provides for non-human transgenic animals, which are useful for a variety of purposes, e.g., studying steroid responsiveness *in vivo* in an animal model, identifying therapeutics for inflammatory diseases or toxicity testing. Transgenic
20 animals of the invention include non-human animals containing a first reporter gene (e.g., green fluorescent protein) under the control of a drug or steroid responsive promoter and a second different reporter gene (e.g., yellow fluorescent protein) under the control of a drug and/or cytokine and/or steroid non-responsive promoter. In a preferred embodiment, a vector containing both reporter transgenes is used to make the transgenic
25 animal. In a preferred embodiment, the human *SAA1* and *SAA2* gene promoters are used. In one embodiment, the reporter genes are the human *SAA1* and *SAA2* genes operatively linked to their own promoters, preferably on a single vector construct. Methods according to the invention are then practiced on the transgenic animals or their tissues, body fluids or cells. Such animals are useful for determining or monitoring drug or
30 steroid responsiveness or dosing drugs or steroids *in vivo*, or studying the side effects of

such drugs or steroids in an animal model. Such animals can also be used for studying drugs that are not primarily known to be anti-inflammatory or immune modifying, to establish whether they have an effect on inflammatory or immune processes (e.g., a side effect) for which the *SAA1* and *SAA2* transgenes provide a readout. An alternative
5 embodiment would follow the above strategy using, for example, the human *SAA1* and human *CRP* gene promoters or the human *SAA2* and human *CRP* gene promoters.

Methods for obtaining transgenic non-human animals are well known in the art. For insertion, the *SAA1* reporter and *SAA2* reporter constructs are added to the embryonic stem (ES) cells under appropriate conditions for the insertion method chosen, as is known
10 to the skilled artisan. For example, if the ES cells are to be electroporated, the ES cells and constructs are exposed to an electric pulse using an electroporation machine following the manufacturer's guidelines for use. After electroporation, the ES cells are typically allowed to recover under suitable incubation conditions. The cells are then screened for the presence of the *SAA1* and *SAA2* construct(s). Where more than one
15 construct is to be introduced into the ES cell, each construct can be introduced simultaneously or one at a time. In a preferred embodiment, a single construct having both the *SAA1* reporter and the *SAA2* reporter (*SAA1/SAA2* construct) is used.

After suitable ES cells containing the *SAA1/SAA2* construct in the proper location have been identified, the cells can be inserted into an embryo. Insertion may be
20 accomplished in a variety of ways known to the skilled artisan, however a preferred method is by microinjection. For microinjection, about 10-30 cells are collected into a micropipet and injected into embryos that are at the proper stage of development to permit integration of the foreign ES cell containing the *SAA1/SAA2* construct into the developing embryo. For instance, the transformed ES cells can be microinjected into
25 blastocytes. The suitable stage of development for the embryo used for insertion of ES cells is very species dependent, however for mice it is about 3.5 days. The embryos are obtained by perfusing the uterus of pregnant females. Suitable methods for accomplishing this are known to the skilled artisan.

While any embryo of the right stage of development is suitable for use, preferred
30 embryos are male. In mice, the preferred embryos also have genes coding for a coat color that is different from the coat color encoded by the ES cell genes. In this way, the

offspring can be screened easily for the presence of the *SAA1/SAA2* construct by looking for mosaic coat color (indicating that the ES cell was incorporated into the developing embryo). Thus, for example, if the ES cell line carries the genes for white fur, the embryo selected carries the genes for black or brown fur.

5 After the ES cell has been introduced into the embryo, the embryo may be implanted into the uterus of a pseudopregnant foster mother for gestation. While any foster mother may be used, the foster mother is typically selected for her ability to breed and reproduce well, and for her ability to care for the young. Such foster mothers are typically prepared by mating with vasectomized males of the same species. The stage of
10 the pseudopregnant foster mother is important for successful implantation, and it is species dependent. For mice, this stage is about 2-3 days pseudopregnant.

Offspring that are born to the foster mother may be screened initially for mosaic coat color where the coat color selection strategy (as described above, and in the appended examples) has been employed. In addition, or as an alternative, DNA from tail
15 tissue of the offspring may be screened for the presence of the *SAA1/SAA2* construct using Southern blots and/or PCR as described above. Offspring that appear to be mosaics may then be crossed to each other, if they are believed to carry the *SAA1/SAA2* construct in their germ line, in order to generate homozygous knockout animals. Homozygotes may be identified by Southern blotting of equivalent amounts of genomic DNA from
20 mice that are the product of this cross, as well as mice that are known heterozygotes and wild type mice.

Other means of identifying and characterizing the *SAA1/SAA2* offspring are available. For example, Northern blots are useful for probing the mRNA for the presence or absence of transcripts encoding one or both of the marker genes. In addition, Western
25 blots are useful to assess the level of expression of the marker gene in various tissues of the offspring by probing the Western blot with an antibody against one or both marker proteins, where this gene is expressed. Finally, *in situ* analysis (such as fixing the cells and labeling with antibody) and/or FACS (fluorescence activated cell sorting) analysis of various cells from the offspring can be conducted using suitable antibodies to look for the
30 presence or absence of the *SAA1/SAA2* construct gene product.

Exemplification

Example 1: Differential *SAA1* and *SAA2* promoter engagement in a series of unmodified and modified promoter reporter constructs transfected into human HepG2 hepatoma cells using various combinations of IL-1, IL-6 and glucocorticoids.

5 SAA Promoter Luciferase Reporter Constructs

The pGL2-SAA2pt construct, which contains 1.2kb of the human *SAA2* promoter upstream of a luciferase reporter was generated as follows. A 1196 bp of the promoter region and 22 bp of the first exon of the human acute phase *SAA2* gene was amplified by PCR with the introduction of MluI and XhoI restriction sites at the 5' and 3' ends respectively (5' oligonucleotide: 5'-AAGAATTCACGCGTCCATGCATGTTGCGGCCGCTTGGCCATCCTT-10 TACTTCCT-3' (SEQ ID NO: 8); 3' oligonucleotide: 5'-TTGAATTCCTCGAGCAGGTA-CCATACATATGTAGCTGAGCTGCGGGTCC-3' (SEQ ID NO:9). The PCR product was subsequently cloned into the multiple-cloning site of the pGL2-Basic vector (Promega, Madison, WI, USA) which is located upstream of a luciferase reporter gene.

15 The pGL2-SAA1pt construct was generated as follows. The proximal 3.1kb of genomic sequence upstream of the human *SAA1* transcription start site plus the full 37 bases of 5'UTR was amplified by polymerase chain reaction (PCR) from human genomic DNA (Roche Biomolecular) using forward and reverse primers, HSAA1PF (5'-GAATTCACGCGTTT-GGGCAGGGAATATACTTATTTATGGAAG-3') (SEQ ID NO:10) and HSAAPR (5'-20 GAATT-CCCATGGTGCTGATCTGTGCTGTAGCTGAGCTGCGGG-3') (SEQ ID NO:11), that incorporate MluI and NcoI restriction sites, respectively. The product was digested with MluI and NcoI and directionally cloned into a pGL2 vector which had been modified to include an NcoI site at the start of the luciferase coding sequence and contains the human *SAA2* 3'UTR (Longley et al. (1999) J. Immunol. 163:4537-45).

25 Constructs pGL2-SAA1[0.7] and pGL2-SAA1[0.25] containing 704 and 233 bases of promoter sequence respectively, were generated from pGL2-SAA1pt by PCR using the forward primers 5'-GAATTCACGCGTGCGTGATT-ATAGCTCACTGCAGCCTTGACC-3' (SEQ ID

NO:12) and 5'-GAATTCACGCGTGGTCT-CCTGCCTG-3' (SEQ ID NO:13) respectively, and the reverse primer HSAAPR.

Constructs pGL2-SAA2[0.7] and pGL2-SAA2[0.25] containing 700 and 239 bases of promoter sequence respectively, were generated from pGL2-SAA2pt by PCR using the forward
5 primers 5'-TATAACGCGTCCTATTTAACGCACCACACTCT-3' (SEQ ID NO:14) and 5'-GAATTCACGCGTGATCTAGCACCTG-3' (SEQ ID NO:15) respectively, and the reverse primer HSAAPR.

Chimeric promoter constructs containing combinations of defined regions of the *SAA1* and *SAA2* promoters were generated by restriction digest of pGL2-SAA1[0.7] and pGL2-SAA2[0.7] with XmaI and heterologous ligation of each linearized distal promoter region with the reciprocal linearized proximal promoter region and vector sequence. The chimeric SAA1/2 promoter contains bases -704 to -164 of *SAA1* and -159 to -1 of *SAA2*. The reciprocal SAA2/1 promoter chimera contains bases -700 to -160 of *SAA2* and -163 to -1 of *SAA1*. The control chimera SAA1/1 was generated by re-ligation of bases -704 to -164 of *SAA1* and -163 to -1 of *SAA1*. The control chimera SAA2/2 was generated by re-ligation of bases -700 to -160 of *SAA2* and -159 to -1 of *SAA2*.

The GREI construct was generated by PCR mutagenesis of pGL2-SAA1[0.7] using primers GREIF (5'-CAGCAAACCTCTCTTGTCCT-3') (SEQ ID NO:16) and GREIR (5'-AGAGAGGTTTGCTGTGCCT-3') (SEQ ID NO:17). The GRED construct was generated by
20 PCR mutagenesis of pGL2-SAA2[0.7] using primers GREDF (5'-CAAGGCACATCTTGTTCCATAGGT-3') (SEQ ID NO:18) and GREDR (5'-GGAACAAGATGTGCCTTGGCAATG-3') (SEQ ID NO:19). The integrity of all constructs was verified by DNA sequencing.

The renilla transfection control plasmid is described elsewhere (Behre et al. (1999) Biotechniques 26:24-6, 28). The constitutive human Glucocorticoid Receptor- α expression
25 plasmid, CMX-GR, was obtained from Dr. Ron Evans, The Salk Institute, La Jolla, CA (Doucas et al. (2000) Proc. Natl. Acad. Sci. USA 97:11893-8).

Cell Culture and Transient Transfection

Human HepG2 hepatoma cells (ATCC) were cultured in DMEM containing 10% FCS, gentamycin, sodium pyruvate and non-essential amino acids (Gibco BRL). Cells were seeded into 24 well plates 24 hours prior to transfection using FuGENE (Roche Biomolecular) as described in Jensen et al. (2000) J. Immunol. 164:5277-86. Cells transfected with *SAA* promoter luciferase reporter constructs and renilla control plasmid, were incubated for 16 to 20 hours before replacement of culture medium with fresh medium alone or fresh medium containing 10ng/ml cytokines and/or dexamethasone and/or RU486 (Mifepristone). IL-1 was purchased from Peprotech. IL-6 was obtained from AstraZeneca. Dexamethasone and RU486 were obtained from Sigma.

Luciferase Assays

Cells were harvested at various times post-treatment, washed in PBS and resuspended in Passive Lysis Buffer (Promega, Madison, WI). Lysates were assayed for luciferase and renilla activity using the LLR and Stop and Glo reagents (Promega) in a dual injection luminometer (Turner Designs, Sunnyvale, CA). Each treatment was carried out in triplicate and the mean ratio of luciferase to renilla activity and standard deviations were calculated. The ratios are expressed relative to untreated controls and are representative of three independent experiments.

RT-PCR

Total RNA was prepared by LiCl Urea extraction (Auffray and Rougeon (1980) Eur. J. Biochem. 107:303-14) from HepG2 cells treated for 24 hours under various experimental conditions. RT-PCR was carried out in a two step process. cDNA was reverse transcribed from 3µg of total cellular RNA in a 25µl reaction containing oligo dT primer, Rnasin, RNase inhibitor and Moloney Murine Leukemia Virus Reverse Transcriptase (Promega) at 42°C for 1 hour. PCR was performed using 2 µl of cDNA product in a 50µl reaction containing 125µM primers, 200µM dNTPs (Pharmacia Amersham, Piscataway, NJ), 1x PCR buffer, 5mM MgCl₂, and AmpliTaq polymerase (Perkin Elmer-Roche, Indianapolis, IN). The forward primer was 5'-CAGACAAATACTTCCATGCT-3' (SEQ ID NO:20); the reverse primer was an equal mix of 5'-TTTTTCCACCTCTTAAGTATTTATTAGA - 3' (SEQ ID NO:21) and 5'-TTTTTCCA-

CCTCTTAAGCATTTATTAGA-3'(SEQ ID NO:22). PCR conditions were as follows: 95°C for 5 minutes, followed by 25 cycles of 94°C for 20 seconds, 51°C for 1 minute, 72°C for 1 minute, followed by 72°C for 5 minutes. Products were separated on 8% polyacrylamide gels at 50v for 24 hours, stained with ethidium bromide and quantified by NIH Image.

5 Computer Analysis

Transcription factor consensus binding site predictions were made using the Signalscan and TESS programs available from the Center for Bioinformatics at the University of Pennsylvania at <http://www.cbil.upenn.edu>. Sequence alignments were carried out using the ClustalW program (Thompson et al. (1994) Nucleic Acids Res. 22:4673-4680) available at http://pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page=/NPSA/npsa_clustalwan.html.

Sequence Alignment Of The Proximal Promoters Of *SAA1* And *SAA2*

Alignment of 0.7kB of the *SAA1* and *SAA2* sequences immediately upstream of their respective transcription start sites, using the ClustalW program, revealed a very high degree of sequence identity (87%) in the proximal ~450bp, upstream of which the sequences exhibit a markedly decreased level of identity and many regions of non-contiguity. The alignment of the highly conserved proximal promoter regions is depicted in Figure 1. Within this alignment there are two short non-contiguous regions that each mandate the introduction of a gap of more than one residue into one of the promoter sequences. These "deletions" are in *SAA1* relative to positions -207 to -199 in *SAA2* and in *SAA2* relative to positions -43 to -40 of *SAA1*. Close visual inspection revealed a putative 15 base pair GRE consensus sequence (GGCACATCTTGTTCC) (SEQ ID NO:23) (Scheidereit et al. (1983) Nature 304:749-52) in *SAA1* (from -208 to -194 of SEQ ID NO:1) that encompasses the first of these non-contiguous regions. These residues are also present in *SAA2* (within the sequence from -213 and -190 of SEQ ID NO:2) but are disrupted" by 9 residues from -207 to -199 that have no counterparts in the corresponding location in *SAA1* (i.e., between *SAA1* residues -203 and -202).

Transcriptional Regulation Of The *SAA1* And *SAA2* Promoters *In Vitro* By Cytokines And Glucocorticoids

To establish the extent to which the *SAA1* and *SAA2* promoters exhibit qualitatively and quantitatively similar responses to cytokines, and to determine whether the putative *SAA1* GRE defined above is functionally active, various reporter constructs containing native and modified *SAA1* and *SAA2* promoters were assayed for their responsiveness to cytokines and glucocorticoids *in vitro*. HepG2 cells transfected with either of the *A-SAA* promoter luciferase reporter constructs, pGL2-SAA1pt or pGL2-SAA2pt, were treated with cytokines for 3, 6, 9 and 24 hours. The *SAA2* promoter was moderately induced by IL-1 alone or IL-6 alone and synergistically induced by the simultaneous addition of both cytokines (Figure 2A). IL-1 driven readout increased from 3 to 24 hours, whereas IL-6 driven readout was highest at 3 hours and decreased through 24 hours. The synergistic response to dual treatment with IL-1 plus IL-6 followed a kinetic profile similar to that observed for IL-6 alone. These results were all in accord with data previously reported by us (Uhlir et al. (1997) J. Immunol. Meth. 203:123-30). The *SAA1* promoter exhibited transcription induction profiles in response to single and dual cytokine treatments that were qualitatively and kinetically similar to those of the *SAA2* promoter (Figure 2B). However, *SAA2* appeared to have a considerable (~ 2-3 fold) quantitative transcriptional advantage over *SAA1* in response to all three cytokine treatments. Treatment of transfected cells with dexamethasone alone had no effect on the *SAA1* promoter. However, co-treatment of transfected cells with 50nM dexamethasone enhanced the cytokine driven induction of the *SAA1* promoter approximately two-fold for all treatments at all timepoints (Figure 2B). In contrast, dexamethasone had no measurable effect on *SAA2* promoter activity under any of the assay conditions (Figure 2A). These data establish that the *SAA1* and *SAA2* genes respond differentially to glucocorticoids in the context of an ongoing cytokine dependent transcriptional induction.

A construct containing only 235 bases of the *SAA1* promoter (pGL2-SAA1[0.25]) retained all of the quantitative, qualitative and kinetic aspects of cytokine responsiveness and glucocorticoid enhancement exhibited by constructs containing 3.1kb of sequence upstream of the *SAA1* transcription start site, suggesting that all of the critical control elements engaged by the most important inflammatory mediators are located in this short region (data not shown).

Dose dependent glucocorticoid enhancement of cytokine driven *SAA1* promoter activity

To determine whether the non-responsiveness of the *SAA1* and *SAA2* promoters to dexamethasone alone and of the *SAA2* promoter to dexamethasone in the context of cytokine induction was due to sub-optimal dosing, a range of dexamethasone concentrations was assayed.

5 HepG2 cells transfected with either pGL2-SAA1pt or pGL2-SAA2pt were treated with 10nM, 50nM, 100nM, 500nM or 1µM dexamethasone in the presence or absence of IL-1 plus IL-6 for 4 hours (Figure 3). Neither promoter showed any response to dexamethasone alone, even at the highest dose used. In contrast to the cytokine driven transcriptional readout from the *SAA2* promoter, which could not be enhanced by dexamethasone at any concentration, the *SAA1* promoter exhibited a clear dose dependent enhancement of transcriptional activity. This suggests that the dexamethasone enhancement of cytokine driven *SAA1* promoter activity involves specific receptor mediated events, most likely via glucocorticoid receptors (GRs).

The enhancement of cytokine driven *SAA1* promoter transcriptional activity by glucocorticoids is glucocorticoid receptor (GR) dependent.

15 To establish that the enhancement of cytokine dependent *SAA1* promoter transcriptional activity by glucocorticoids is mediated by the GR, cytokine and dexamethasone treatments similar to those described above were carried out in the presence of the GR antagonist RU486 (Mifepristone). HepG2 cells transfected with pGL2-SAA1pt were treated with IL-1 plus IL-6, in the presence or absence of 100nM dexamethasone and/or 10nM RU486 for 4 hours (Figure 4).

20 The presence of RU486 alone had no measurable effect on the level of cytokine driven *SAA1* promoter transcriptional activity. However, RU486 completely blocked the capacity of dexamethasone to quantitatively enhance the induction of the *SAA1* promoter by cytokines, limiting the transcriptional readout to that observed in transfected cells treated only with cytokines. This established that the GR is a requisite component in mediating the dexamethasone enhancement of cytokine driven *SAA1* transcriptional activity.

The effect of GR over-expression on the capacity of dexamethasone to modify *SAA1* and *SAA2* gene transcriptional activity

HepG2 cells have been reported to express only low levels of GR (Baumann et al. (1990) J. Biol. Chem. 265:22275-81). To determine whether the non-response of both promoters to dexamethasone alone, and that of the *SAA2* promoter to dexamethasone in the context of cytokine induction, is due to cellular GR levels that are below a functional threshold, *SAA1* and *SAA2* transcriptional readout was measured in HepG2 cells co-transfected with a constitutive GR expression construct after treatment with various combinations of cytokines and dexamethasone (Figure 5).

The *SAA1* and *SAA2* promoters remained non-responsive to dexamethasone alone in HepG2 cells co-transfected with 5, 25 or 50ng/well of GR expression construct together with pGL2-SAA1pt or pGL2-SAA2pt. However, in the context of cytokine induction of the *SAA1* promoter, the dexamethasone enhancement of cytokine driven transcriptional readout could be augmented by co-transfection with the higher amounts (i.e., 25 or 50ng/well) of GR expression construct (Figure 5A). These results suggest that the glucocorticoid signaling capacity of native HepG2 cells is not maximized with respect to engagement of the *SAA1* promoter GRE. In contrast, co-transfection of GR expression vector could not bring about a dexamethasone dependent enhancement of cytokine driven transcriptional readout from the *SAA2* promoter even when cells transfected with the highest levels of GR construct were treated with the highest concentrations of dexamethasone (Figure 5B). The latter results establish that the *SAA2* promoter is truly non-responsive to glucocorticoids.

Chimeric promoters containing the putative *SAA1* GRE retain glucocorticoid responsiveness

The *SAA1* and *SAA2* proximal promoter regions each contain XmaI restriction enzyme sites that are similarly positioned in a highly conserved region immediately downstream of the NF-IL6 site, which itself is immediately downstream of the “GRE” region (Figure 1). The XmaI site was used to generate chimeras in which the *SAA1* and *SAA2* “GRE” regions could be reciprocally ligated to the *SAA1* and *SAA2* proximal promoter regions spanning the approximately 160bp adjacent to the transcription start site of each gene. The proximal promoter regions are highly conserved (93% identical) and each contain the critically important NfκappaB

site in addition to a putative site (between -110 and -102 of *SAA1* and -106 and -98 of *SAA2*) for the transcriptional repressor YY-1; the major difference is a “deletion” in the *SAA2* promoter of four residues that are present in the *SAA1* promoter between residues -44 and -39 (Figure 1). The experiments outlined above established that all of the major cytokine and glucocorticoid response elements, together with the promoter feature that confers an apparent baseline and cytokine responsive transcriptional advantage to the *SAA2* gene are located within 250 bases of the transcription start site. The chimeric constructs were used to determine the locations of the elements that mandate qualitative and quantitative transcriptional differences between the *SAA1* and *SAA2* genes relative to the Xma1 site.

Constructs SAA1/1 and SAA2/1, each of which contain the proximal 163bp of the *SAA1* promoter region, exhibited basal and cytokine driven levels of transcriptional activity that are characteristic of the unmodified *SAA1* promoter (Figure 6). Similarly, constructs SAA1/2 and SAA2/2, each of which contain the proximal 159bp of the *SAA2* promoter region, had basal and cytokine driven levels of transcriptional activity that are characteristic of the unmodified *SAA2* promoter. Taken together, these experiments suggest that quantitative differences in both the basal and cytokine-driven transcriptional regulation of the *SAA1* and *SAA2* genes are mandated by minor sequence differences between the respective promoters in the region downstream of the Xma1 site. Constructs SAA1/1 and SAA1/2, which contain the distal region of the *SAA1* promoter (i.e., upstream of the Xma1 site) including the putative GRE, were each responsive to dexamethasone in the presence of cytokines. Constructs SAA2/1 and SAA2/2 contain the distal region of the *SAA2* promoter and were each non-responsive to dexamethasone. These data strongly suggest that a genetic element in the region between bases -704 and -164 of the *SAA1* promoter, most likely the sequence between -208 and -194 that conforms to the GRE consensus, confers the property of glucocorticoid modifiable transcriptional activity to the *SAA1* gene.

Confirmation that the putative GRE in *SAA1* is functional

Site directed mutagenesis experiments were performed to determine whether the putative *SAA1* GRE is functional and to exclude the possibility that subtle differences in genomic context, rather than intrinsic sequence differences in the putative *SAA1* GRE and *SAA2* “disrupted GRE”, mandate the differential dexamethasone responsiveness of the genes (and chimeric derivatives

thereof). Two modified constructs were generated: the GREI construct contains an *SAA1* promoter with a 9 residue sequence (GCAAACCTC) (Nucleotides -207 to -199 of SEQ ID NO:2) inserted into the GRE to form an “*SAA2*-like disrupted GRE”; the GRED construct contains an *SAA2* promoter in which the same 9 residues have been deleted to form an “*SAA1*-like GRE” (Figure 7A). The GREI and GRED constructs each retained the basal and cytokine driven levels of transcriptional activity that are characteristic of the unmodified parental promoters from which they were derived. However, the GREI construct had “lost” the capacity to respond to dexamethasone in the presence of cytokines, whereas the GRED construct had “gained” this property (Figure 7B), thereby establishing that the *SAA1* GRE is functional and is both necessary and sufficient to confer glucocorticoid responsiveness in the context of cytokine stimulation.

Example 2: Use of the RT-PCR assay to establish that the ratio of SAA1 and SAA2 products in HepG2 cells treated with IL-1 plus IL-6 changes according to whether glucocorticoid is present, in a manner analogous to that defined in promoter-reporter studies.

To determine whether the results obtained using the *SAA1* and *SAA2* promoter luciferase reporter constructs accurately reflect the regulation of the endogenous genes with respect to cytokines and glucocorticoids, an RT-PCR method was developed whereby the relative proportions of the transcription products of each gene could be directly compared. The *SAA1* and *SAA2* mRNAs, although highly similar (91% identical overall), differ significantly in the central region of their 3'UTRs; the *SAA1* mRNA 3'UTR relative to that of the *SAA2* mRNA 3'UTR has four “deletions” totaling 26 residues (Figure 8A).

Forward and reverse PCR primers were designed, each of which can bind cDNA derived from either A-SAA mRNA (Figure 8A). RT-PCR using these primers generates bands of 335 and 361 base pairs corresponding to products generated from the *SAA1* and *SAA2* mRNAs respectively. In addition, the primers span intron 3 of each gene, thereby permitting products of amplification from contaminating genomic DNA to be identified. The ratio of 335bp to 361bp products, as determined by image analysis following resolution on 8% polyacrylamide gels

reflects the relative concentrations of cellular SAA1 and SAA2 mRNAs and serves as a surrogate measure or readout of the transcriptional activation of the *SAA1* and *SAA2* promoters.

The above RT-PCR method was applied to total RNA from untreated and treated HepG2 cells. Products derived from SAA1 or SAA2 mRNA were not detected in untreated cells or following treatment with dexamethasone alone (Figure 8B, lanes 1 and 2). However, the ratio of the levels of the SAA1 to SAA2 PCR products was approximately 2:5 following treatment with IL-1 and IL-6 (Figure 8B, lane 3), indicating that the endogenous *SAA2* gene has a significant transcriptional advantage (i.e., ~2.5 fold) when induced by cytokines in the absence of glucocorticoids. In contrast, the ratio of the levels of the SAA1 to SAA2 PCR products from cells treated with IL-1 and IL-6 plus dexamethasone was 5:4 (Figure 8B, lane 4), indicating that the above cytokine driven transcriptional advantage of the *SAA2* promoter is superceded by a modest *SAA1* transcriptional advantage in the presence of glucocorticoids. Thus, the responses of the endogenous genes to different combinations of pro-inflammatory mediators paralleled those observed in experiments using isolated promoters to drive a quantifiable reporter, thereby establishing that the *SAA1* GRE is functional when in its native genomic and cellular environment.

Example 3: Evaluation of the glucocorticoid-dependent differential transcriptional activities of the *SAA1* and *SAA2* genes for use in determining steroid responsiveness in patients with diseases that have an inflammatory component.

Inflammatory bowel diseases (IBDs) (e.g., Crohn's and ulcerative colitis) are often treated with steroids, the efficacy of which is variable, both *ab initio* and over time. The assay according to the invention, which is based on the ratio of SAA1 to SAA2 mRNAs, is a useful tool for predicting and/or assessing steroid responder status. The assay is used to determine whether subjects suffering from IBD, for example, fall into four general categories: (i) in remission (not currently taking steroids but may have taken steroids in the past; (ii) steroid refractory (still with active disease, despite at least four weeks of steroid treatment); (iii) steroid dependent (quiescent on high doses of steroids, but tending to flare up if steroids are withdrawn); or (iv) active disease (naïve with

respect to steroid therapy or not having taken steroids for at least six months (e.g., due to previous lack of efficacy and/or side effects).

After informed consent has been given, patients' disease status is evaluated and a 10 ml blood sample and buccal swab (e.g., obtained by gently rubbing the inside of the cheek with a small brush) is obtained. Alternatively, a biopsy sample may be obtained according to standard methods. The blood sample may be taken according to methods known in the art, e.g., in a standard heparin or EDTA blood collection tube or a blood tube which is specially treated or supplemented with an RNA preservative solution that inhibits RNase activity or the like (e.g., a PAXgene™ Blood RNA Tube, Qiagen, Hilden, Germany). The buccal swab is taken using, for example, a CYTO-PAK CytoSoft™ brush (Medical Packages Corp., Camarillo, CA) and is placed on ice to avoid degradation of the mRNA, or into an RNA preservative solution to inhibit RNase activity or the like.

Proportional RT-PCR analysis to determine the ratio of SAA1 mRNA to SAA2 mRNA is then performed according to the method of Example 2. Data is analyzed to establish the extent to which particular SAA1:SAA2 ratios are associated with particular steroid response phenotypes. The assay may form the basis of a patient care strategy wherein the ratio of SAA1 mRNA to SAA2 mRNA in nucleated blood cells and/or buccal cells and/or biopsy sample and/or tissue sample is correlated with (i) current clinical response to steroid therapy, and/or (ii) past clinical response to steroid therapy, and/or (iii) future clinical response to steroid therapy.

Equivalents

The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting of the invention described herein.